Objective: The objective of the study was to investigate the effect of multiple clinical parameters (age, weight, blood types, and bleeding types) on FVIII pharmacokinetic parameters (PK parameters) in adult patients with severe hemophilia A (SHA), draw up individualized preventive treatment plans, and observe clinical efficacy. Methods: Forty SHA patients treated in our hospital from January 2018 to May 2019 were enrolled, with their age, weight, blood types, bleeding types, and PK parameters measured to analyze the effects of clinical parameters on PK parameters. Individualized preventive treatment was developed, and patients were followed up for 1 year. The annual bleeding rate (ABR), annual joint bleeding rate (AJBR), and annual FVIII dosage were observed and compared before and after treatment. Results: Weight, blood types, and bleeding types could affect the PK parameters of FVIII. A prophylaxis plan was formulated under the guidance of FVIII half-life. After 1 year of follow-up, the mean ABR dropped from 36.54 to 4.06, decreased by 88.9%, the mean AJBR dropped from 28.36 to 2.75, decreased by 90%, and annual FVIII dosage increased by 47%. The dosage of FVIII in 8 patients after was less than that before prophylaxis, and the average half-life time of these 8 patients was 13.32 h. Conclusions: (1) Weight, blood types, and bleeding types of adult SHA patients could affect FVIII half-life. As body mass index increased, FVIII half-life was significantly prolonged. The FVIII half-life of patients with type O blood was significantly shorter than those with other blood types, and the FVIII half-life of knee joint bleeding was conspicuously shorter than those of elbow joint bleeding. (2) Individualized preventive treatment could markedly reduce the number of bleeds. For patients with a long half-life period, the total annual FVIII dosage could be reduced to achieve bleeding prevention.

1.
Rosendaal
FR
,
Palla
R
,
Garagiola
I
,
Mannucci
PM
,
Peyvandi
F
,
Group
SS
.
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
.
Blood
.
2017
;
130
(
15
):
1757
9
. .
2.
Giangrande
PLF
,
Hermans
C
,
O’Mahony
B
,
de Kleijn
P
,
Bedford
M
,
Batorova
A
,
European principles of inhibitor management in patients with haemophilia
.
Orphanet J Rare Dis
.
2018
;
13
(
1
):
66
.
3.
Iorio
A
,
Marchesini
E
,
Marcucci
M
,
Stobart
K
,
Chan
AK
.
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
.
Cochrane Database Syst Rev
.
2011
;(
9
):
CD003429
. .
4.
Hazendonk
H
,
van Moort
I
,
Mathot
RAA
,
Fijnvandraat
K
,
Leebeek
FWG
,
Collins
PW
,
Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?
Blood Rev
.
2018
;
32
(
4
):
265
71
.
5.
Ljung
RCR
.
How i manage patients with inherited haemophilia A and B and factor inhibitors
.
Br J Haematol
.
2018
;
180
(
4
):
501
10
. .
6.
Petrini
P
,
Valentino
LA
,
Gringeri
A
,
Re
WM
,
Ewenstein
B
.
Individualizing prophylaxis in hemophilia: a review
.
Expert Rev Hematol
.
2015
;
8
(
2
):
237
46
. .
7.
HK, CZ, WR
.
Factors affecting the pharmacokinetics parameters of FVIII in patients with hemophilia A
.
Thromb Haemost
.
2019
;
025
(
005
):
897
900
.
8.
Nguyen
GN
,
George
LA
,
Siner
JI
,
Davidson
RJ
,
Zander
CB
,
Zheng
XL
,
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A
.
J Thromb Haemost
.
2017
;
15
(
1
):
110
21
.
9.
Fischer
K
,
Steen Carlsson
K
,
Petrini
P
,
Holmstrom
M
,
Ljung
R
,
van den Berg
HM
,
Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
.
Blood
.
2013
;
122
(
7
):
1129
36
.
10.
Sudevan
R
,
Beenakumari
AA
,
Ganapathy
R
,
Unni
M
,
Vidyadharan
G
,
Sidharthan
N
.
Intermediate dose prophylaxis in adults with haemophilia: a clinical audit from a resource limited setting
.
Indian J Hematol Blood Transfus
.
2020
;
36
(
2
):
374
6
. .
11.
Verma
SP
,
Dutta
TK
,
Mahadevan
S
,
Nalini
P
,
Basu
D
,
Biswal
N
,
A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia – a success story from a resource limited country
.
Haemophilia
.
2016
;
22
(
3
):
342
8
.
12.
Zhang
Y
,
Roberts
J
,
Tortorici
M
,
Veldman
A
,
St Ledger
K
,
Feussner
A
,
Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A
.
J Thromb Haemost
.
2017
;
15
(
6
):
1106
14
.
13.
Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China
.
[Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)]
.
Zhonghua Xue Ye Xue Za Zhi
.
2017
;
38
(
5
):
364
70
. .
14.
Bjorkman
S
,
Blanchette
VS
,
Fischer
K
,
Oh
M
,
Spotts
G
,
Schroth
P
,
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
.
J Thromb Haemost
.
2010
;
8
(
4
):
730
6
.
15.
Powell
JS
.
Longer-acting clotting factor concentrates for hemophilia
.
J Thromb Haemost
.
2015
;
13
(
Suppl 1
):
S167
75
. .
16.
Chen
ZP
,
Li
PJ
,
Li
G
,
Tang
L
,
Zhen
YZ
,
Wu
XY
,
Pharmacokinetic studies of factor VIII in Chinese boys with severe hemophilia a: a single-center study
.
Chin Med J
.
2018
;
131
(
15
):
1780
5
.
17.
Henrard
S
,
Speybroeck
N
,
Hermans
C
.
Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A
.
J Thromb Haemost
.
2011
;
9
(
9
):
1784
90
. .
18.
Lenting
PJ
,
Van Schooten
CJ
,
Denis
CV
.
Clearance mechanisms of von Willebrand factor and factor VIII
.
J Thromb Haemost
.
2007
;
5
(
7
):
1353
60
.
19.
Lundin
B
,
Ljung
R
,
Pettersson
H
;
European Paediatric Network for Haemophilia Management (PEDNET)
.
MRI scores of ankle joints in children with haemophilia: comparison with clinical data
.
Haemophilia
.
2005
;
11
(
2
):
116
22
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.